Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088338 | 0.98 | MAPT (0.56) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| SCHEMBL11512450 | 0.98 | MAPT (0.56) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| SCHEMBL9495920 | 0.98 | MAPT (0.56) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| SCHEMBL5369364 | 0.98 | MAPT (0.56) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| SCHEMBL5859613 | 0.93 | MAPT (0.48) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| Malonic Acid SCHEMBL16458514 | 0.90 | MAPT (0.53) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| SCHEMBL4016679 | 0.84 | MAPT (0.50) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| SCHEMBL5862560 | 0.82 | ABCC4 (0.46) | MAPTABCC4ALDH1A1LMNATSHR | |
| SCHEMBL21439803 | 0.82 | MAPT (0.54) | MAPTABCC4ALDH1A1USP2CYP3A4 | |
| SCHEMBL3804921 | 0.82 | MAPT (0.54) | MAPTABCC4ALDH1A1USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006100606-A2 | PREPARATION OF BETA-AMINO ACID PRECURSORS VIA INDIUM (III) MEDIATED MARKOVNIKOV ADDITION AND KNOEVENAGEL CONDENSATION | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-28 | — | — | WO | claimed |
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7060818-B2 | Synthesis of macrocyclic tetraamido compounds and new metal insertion process | CARNEGIE MELLON UNIVERSITY (US) | 2006-06-13 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | MAPT 4793/4885ABCC4 216/4885ALDH1A1 760/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | MAPT 4799/4885ABCC4 207/4885ALDH1A1 571/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | MAPT 4835/4885ABCC4 344/4885ALDH1A1 557/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | MAPT 4835/4885ABCC4 344/4885ALDH1A1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.